Design of in vitro studies to predict in vivo inhibitory drug-drug interactions

Pharmacological Research

Volumn 38, Issue 2, 1998, Pages 81-88

  Benedetti, M Strolin ^a   Bani, M ^a  

^a Zambon Group SpA   (Italy)

Author keywords

Drug drug interactions; In vitro in vivo predictability; Inhibitors of cytochrome P450 isozymes; Mechanism of enzyme inhibition

Indexed keywords

BUFURALOL; CAFFEINE; CIMETIDINE; CLARITHROMYCIN; CYCLOSPORIN; CYTOCHROME P450 ISOENZYME; DAPSONE; DEBRISOQUINE; DRUG METABOLIZING ENZYME; ERYTHROMYCIN; FLUCONAZOLE; FLUOXETINE; FLUVOXAMINE; FURAFYLLINE; ISONIAZID; ITRACONAZOLE; KETOCONAZOLE; MONOAMINE OXIDASE INHIBITOR; PAROXETINE; PHENYTOIN; RIFABUTIN; SELEGILINE; SEROTONIN UPTAKE INHIBITOR; TERFENADINE;

BLOOD TOXICITY; DRUG INTERACTION; DRUG METABOLISM; ENZYME INHIBITION; FRUIT JUICE; PREDICTION; PRIORITY JOURNAL; REVIEW; SEROTONIN SYNDROME; UVEITIS;

EID: 0032145305     PISSN: 10436618     EISSN: None     Source Type: Journal    
DOI: 10.1006/phrs.1998.0344     Document Type: Article

References (51)

1. 1. Laurence DR, Bennett PN, Brown MJ, eds. Clinical pharmacology, 8th edition, Chapter 6 and 7, Longman Singapore Publishers, 1997.
2. 2. Kessler KM, Lowenthal DT, Warner H, Gibson T, Briggs W, Reidemberg MM. Quinidine elimination in patients with congestive heart failure or poor renal function. N Engl J Med 1974; 290: 706-9.
3. 3. Gioulekas J, Hall A. Uveitis associated with rifabutin therapy. Austral N. Z. J Ophtalmol 1995; 23: 319-21.
4. 4. Lefort A, Launay O, Carbon C. Uveitis associated with rifabutin prophylaxis and itraconazole therapy. Ann Intern Med 1996; 125: 939-40.
5. 5. Lowe SH, Kroon FP, Bollemeyer JG, Stricker BH, van't Wout JW. Uveitis during treatment of disseminated Mycobacterium avium-intracellular complex infection with the combination of rifabutin, clarithromycin and ethambutol. Neth J Med 1996; 48: 211-15.
6. 6. Narang PK, Trapnell CB, Schoenfelder JR et al. Fluconazole and enhanced effect of rifabutin prophylaxis (letter). N Engl J Med 1994; 330: 1316.
7. 7. DATRI 001 Study Group. Coadministration of clarithromycin alters the concentration-time profile of rifabutin. 34th ICAAC, Abstr Book 1994; A2: 3.
8. 8. Lane R, Baldwin D. Selective serotonin reuptake inhibitor-induced serotonin syndrome: review. J Clin Psychopharmacol 1997; 17: 208-21.
9. 9. Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR et al. The cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice. Eur J Clin Pharmacol 1997; 52: 311-15.
10. 10. Bailey DG, Arnold JMO, Munoz C, Spence JD. Grapefruit juice - felodipine interaction: mechanism, predictability, and effect of naringin. Clin Pharmacol Ther 1993; 53: 637-42.
11. 11. Miniscalco A, Lundhal J, Regårdh CG, Edgar B, Eriksson UG. Inhibition of dihydropyridine metabolism in rat and human liver microsomes by flavonoids found in grapefruit juice. J Pharmacol Exp Ther 1992; 261: 1195-9.
12. 12. Lee YS, Lorenzo BJ, Koufis T, Reidemberg MM. Grapefruit juice and its flavonoids inhibit 11β-hydroxysteroid dehydrogenase. Clin Pharmacol Ther 1996; 59: 62-71.
13. 13. Rau SE, Bend JR, Arnold JMO, Tran LT, Spence JD, Bailey DG. Grapefruit juice - terfenadine single-dose interaction: magnitude, mechanism, and relevance. Clin Pharmacol Ther 1997; 61: 401-9.
14. 14. Schmiedlin-Ren P, Edwards DJ, Fitzsimmons ME, He K, Lown KS, Woster PM et al. Mechanism of enhanced oral availability of CYP 3A4 substrates by grapefruit constituents. Drug Metab Dispos 1997; 25: 1228-33.
15. 15. Fukuda T et al. Pharmacogenetics 1997; 7: 391-6.
16. 16. Tarrus E, Garni J, Roberts DJ, Spickett RGW, Celdran E, Segura J. Accumulation of caffeine in health volunteers treated with furafylline. Br J Clin Pharmacol 1987; 23: 9-18.
17. 17. Boobis AR. Prediction of inhibitory drug-drug interactions by studies in vitro. In: Pacifici GM, Fracchia GN, eds. Advances in drug metabolism in man. European Commission, ECSC-EC-EAEC, Brussels-Luxembourg, 1995: 515-39.
18. 18. Strolin Benedetti M. Some pharmacological and clinical aspects of reversible MAO inhibitors. In: Paton W, Mitchell J, Turner P, eds. Proceedings of IUPHAR 9th international congress of pharmacology. Basingstoke and London: MacMillan Press Ltd, 1984: pp. 219-30.
19. 19. Jeppesen U, Loft S, Poulsen HE, Brosen K. A fluvoxamine-caffeine interaction study. Pharmacogenetics 1996; 6: 213-22.
20. 20. Parkinson A. Biotransformation of xenobiotics, In: Klaassen CD, ed. Toxicology - the basic science of poisons, 5th edition. McGraw-Hill, 1996: pp. 113-86.
21. 21. Odocha O, Kelly B, Trimble S, Murigande C, Toussaint RM, Callender CO. Cost-containment strategies in transplantation: the utility of cyclosporine-ketoconazole combination therapy. Transplant Proc 1996; 28: 907-9.
22. 22. The European Agency for the Evaluation of Medicinal Products, Human Medicines Evaluation Unit. Note for guidance on the investigation of drug interactions. London, 17 March 1997, CPMP/EWP/560/95.
23. 23. Houston JB. Utility of in vitro drug metabolism data in predicting in vivo metabolic clearance. Biochem Pharmacol 1994; 47: 1469-79.
24. 24. Grant MH, Duthie SJ, Gray AG, Burke MD. Mixed function oxidase and UDP-glucuronyltransferase activities in the human Hep G2 hepatoma cell line. Biochem Pharmacol 1988; 37: 4111-16.
25. 25. Gan LL, Moseley MA, Khosla B, Augustijns PF, Bradshaw TP, Hendren RW et al. CYP3A-like cytochrome P450-mediated metabolism and polarized efflux of cyclosporin A in Caco-2 cells. Interaction between the two biochemical barriers to intestinal transport. Drug Metab Dispos 1996; 24: 344-9.
26. 26. Prueksaritanont T, Gorham LM, Hochman JH, Tran LO, Vyas KP. Comparative studies of drug-metabolizing enzymes in dog, monkey, and human small intestines, and in Caco-2 cells. Drug Metab Dispos 1996; 24: 634-42.
27. 27. Raeissi SD Guo Z, Dobson GL, Artursson P, Hidalgo IJ. Comparison of CYP3A activities in a subclone of Caco-2 (TC7) and human intestine. Pharmacol Res 1997; 14: 1019-25.
28. 28. Böttiger Y, Dostert P, Strolin Benedetti M, Bani M, Fiorentini F, Casati M et al. Involvement of CYP2D6 but not CYP2C19 in nicergoline metabolism in humans. Br J Clin Pharmacol 1996; 42: 701-11.
29. 29. Mancy A, Broto P, Dijols S, Dansette PM, Mansuy D. The substrate binding site of human liver cytocrome P450 2C9: an approach using designed tienilic acid derivatives and molecular modeling. 9th Int Conference on Cytochrome P450, 23-27 July 1995, Abstract Book p. 241.
30. 30. Fuhr U, Strobl G, Manaut F, Anders E, Sörgel F, López-de-Briñas E, Chu DTW et al. Quinolone antibacterial agents: relationship between structure and in vitro inhibition of the human cytochrome P450 isoform CYP1A2. Mol Pharmacol 1993; 43: 191-9.
31. 31. Fassbender M, Fuhr U, Brandt J, Strobl G, Wolff T, Greim H et al Molecular modelling study on inhibitors of the human cytochrome P450 isoform 1A2. 9th Int Conference on Cytochrome P450, 23-27 July 1995, Abstract Book p. 167.
32. 32. Segura J, Roberts DJ, Tarrus E. The influence of structure on the accumulation of caffeine induced by methyl xanthine derivatives. J Pharm Pharmacol 1989; 41: 129-31.
33. 33. Lozano JJ, López-de-Briñas E, Centeno NB, Guigó R, Sanz F. Three-dimensional modelling of human cytochrome P450 1A2 and its interaction with caffeine and MeIQ. J Comput-Aided Mol Design 1997; 11: 395-408.
34. 34. Kedderis GL. Pharmacokinetics of drug interactions. In: Li AP, ed. Drug-Drug interactions: scientific and regulatory perspectives. San Diego, CA: Academic Press, 1997: 189-203.
35. 35. Cornish-Bowden A. Why an uncompetitive inhition so rare? A possible explanation with implication for the design of drugs and pesticides. FEBS Lett 1986; 203: 3-6.
36. 36. Westley AM, Westley J. Enzyme inhibition in open systems: superiority of uncompetitive agents. J Biol Chem 1996; 271: 5347-52.
37. 37. Boobis AR, Murray S, Hampden CE, Davies DS. Genetic polymorphism in drug oxidation: in vitro studies of human debrisoquine 4-hidroxylase and bufuralol 1′-hidroxylase activities. Biochem Pharmacol 1985; 34: 65-71.
38. 38. Boobis AR, Davies DS. Human cytochrome P-450. Xenobiotica 1984; 14: 151-85.
39. 39. Min DI, Ku Y, Geraets DR, Lee H. Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers. J Clin Pharmacol 1996; 36: 469-76.
40. 40. Kutt H. Interactions of antiepileptic drugs. Epilepsia 1975; 16: 393-402.
41. 41. Strolin Benedetti M, Tocchetti P, Rocchetti M, Martignoni M, Marrari P, Poggesi I, Dostert P. Enantioselective recognition of two anticonvulsants, FCE 26743 and FCE 28073, by MAO, and relationship between MAO-B inhibition and FCE 26743 concentrations in rat brain. In: Yu PM, Tipton KF, Boulton AA, eds. Progress in brain research. Elsevier Sci., 1995: vol 106.
42. 42. Heinonen EH, Anttila MI, Nyman LM, Pyykkö KA, Vuorinen JA, Lammintausta RAS. Inhibition of platelet monoamine oxidase type B by selegiline. J Clin Pharmacol 1997; 37: 597-601.
43. 43. Heinonen EH, Anttila MI, Karnani HL, Nyman LM, Vuorinen JA, Pyykkö KA et al. Desmethylselegiline, a metabolite of selegiline, is a irreversible inhibitor of monoamine oxidase type B in humans. J Clin Pharmacol 1997; 37: 602-9.
44. 44. Shin HS. Metabolism of selegiline in humans. Identification, excretion, and stereochemistry of urine metabolites. Drug Metab Dispos 1997; 25: 657-62.
45. 45. Park BK, Kitteringham NR, Pirmohamed M, Tucker GT. Relevance of induction of human drug-metabolizing enzymes: pharmacological and lexicological implications. Br J Clin Pharmacol 1996; 41: 477-91.
46. 46. Tingle MD, Coleman MD, Park BK. The effect of preincubation with cimetidine on the N-hydroxylation of dapsone by human liver microsomes. Br J Clin Pharmacol 1991; 32: 120-3.
47. 47. Sesardic D, Boobis AR, Murray BP, Murray S, Segura J, De La Torre R et al. Furafylline is a potent and selective inhibitor of cytochrome P450 1A2 in man. Br J Clin Pharmacol 1990; 29: 651-63.
48. 48. Eagling VA, Tjia JF, Back DJ. Differential selectivity of cytochrome P450 inhibitors against four probe substrates in human and rat liver microsomes. Br J Clin Pharmacol 1996; 42: 673P.
49. 49. Stryckmans P, Duff GW, Fracchia GN. Efficacy and safety of cytokines for human therapy. Cytokine 1993; 5: 180-4.
50. 50. Abdel-Razzak Z, Loyer P, Fautrel A, Gautier JC, Corcos L, Turlin B et al. Cytokines down-regulate expression of major cytochrome P-450 enzymes in adult human hepatocytes in primary culture. Mol Pharmacol 1993; 44: 707-15.
51. 51. Shimada T, Yamazaki H, Mimura M, Inui Y, Guengerich FP. Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. J Pharmacol Exp Ther 1994; 270: 414-23.